Invesaro

Stocks Comparison

Cardiff Lexington vs Oncology Institute: revenue, profit, margins and growth compared

Cardiff Lexington brought in $11.5M of revenue in fiscal 2025, Oncology Institute $502.7M in fiscal 2025. Revenue changed by +39.5% at Cardiff Lexington and +27.8% at Oncology Institute on the year before, so Cardiff Lexington grew faster. Cardiff Lexington kept -47.7% of its revenue as net profit, Oncology Institute -12.1%.

Side by side, latest fiscal year

CDIXTOI
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$11.5M$502.7M
Revenue growth+39.5%+27.8%
Net income-$5.5M-$60.6M
Net margin-47.7%-12.1%
Free cash flown/a-$27.8M
Free cash flow marginn/a-5.5%
Earnings per share (diluted)n/a-$0.54
Cash$318.5K$33.6M
Debt$18.6M$77.4M
Price to earningsn/an/a
Market value$6.6M$522.8M
Dividend yieldn/an/a
Rank by revenue in sector#508 of 742 · Health care#204 of 742 · Health care

Over the years

Revenue
CDIX FY2018: $2.2MCDIX FY2019: $4.5MCDIX FY2020: $3.5MCDIX FY2021: $9.9MCDIX FY2022: $10.7MCDIX FY2023: $11.9MCDIX FY2024: $8.3MCDIX FY2025: $11.5MTOI FY2020: $187.5MTOI FY2021: $203MTOI FY2022: $252.5MTOI FY2023: $324.2MTOI FY2024: $393.4MTOI FY2025: $502.7MFY18FY19FY20FY21FY22FY23FY24FY25
CDIX $11.5MTOI $502.7M
Net income
CDIX FY2018: -$6.3MCDIX FY2019: -$7.2MCDIX FY2020: -$2.8MCDIX FY2021: $666.3KCDIX FY2022: -$5.4MCDIX FY2023: $3MCDIX FY2024: -$3.3MCDIX FY2025: -$5.5MTOI FY2020: -$14.3MTOI FY2021: -$10.9MTOI FY2022: $152KTOI FY2023: -$83.1MTOI FY2024: -$64.7MTOI FY2025: -$60.6MFY18FY19FY20FY21FY22FY23FY24FY25
CDIX -$5.5MTOI -$60.6M
Net margin
CDIX FY2018: -281.3%CDIX FY2019: -158.1%CDIX FY2020: -82.2%CDIX FY2021: 6.7%CDIX FY2022: -50.8%CDIX FY2023: 25.5%CDIX FY2024: -39.9%CDIX FY2025: -47.7%TOI FY2020: -7.6%TOI FY2021: -5.4%TOI FY2022: 0.1%TOI FY2023: -25.6%TOI FY2024: -16.4%TOI FY2025: -12.1%FY18FY19FY20FY21FY22FY23FY24FY25
CDIX -47.7%TOI -12.1%
Revenue growth
CDIX FY2019: +103.9%CDIX FY2020: -24.0%CDIX FY2021: +186.1%CDIX FY2022: +8.2%CDIX FY2023: +10.8%CDIX FY2024: -30.2%CDIX FY2025: +39.5%TOI FY2021: +8.3%TOI FY2022: +24.4%TOI FY2023: +28.4%TOI FY2024: +21.3%TOI FY2025: +27.8%FY19FY20FY21FY22FY23FY24FY25
CDIX +39.5%TOI +27.8%
Free cash flow
CDIX FY2018: -$2MCDIX FY2020: -$903.4KCDIX FY2021: -$853.5KCDIX FY2022: -$1.2MTOI FY2020: -$686KTOI FY2021: -$35.5MTOI FY2022: -$67.3MTOI FY2023: -$40.9MTOI FY2024: -$30.3MTOI FY2025: -$27.8MFY18FY20FY21FY22FY23FY24FY25
CDIX -$1.2MTOI -$27.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about Cardiff Lexington and Oncology Institute

Which is bigger by revenue, Cardiff Lexington or Oncology Institute?

Oncology Institute is bigger by revenue: $502.7M in fiscal 2025, against $11.5M for Cardiff Lexington in fiscal 2025.

Which keeps more of its revenue as profit, Cardiff Lexington or Oncology Institute?

Cardiff Lexington had a net margin of -47.7% in fiscal 2025; Oncology Institute had -12.1% in fiscal 2025.

Which grew revenue faster, Cardiff Lexington or Oncology Institute?

In their latest fiscal years revenue changed by +39.5% at Cardiff Lexington and +27.8% at Oncology Institute.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies